Paid Clinical Trials for Acute Myeloid Leukemia

Showing 21 – 40 of 115 results

Quality of Life Model for Older Patients With AML

by CTG

in Acute Myeloid Leukemia, AML, Adult

Other

Florida

Deadline:

03/01/2026

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

by CTG

in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Other

California

Deadline:

04/07/2030

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

by CTG

in Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Myeloid Sarcoma

Other

Texas

Deadline:

12/31/2027

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

by CTG

in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia

Other

Georgia

Deadline:

09/01/2026

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

by CTG

in Acute Myeloid Leukemia

Other

Virginia

Deadline:

10/31/2029

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

by CTG

in Acute Myeloid Leukemia

Other

Florida

Deadline:

12/01/2027

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

by CTG

in Multiple Myeloma, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome, Haematological Malignancy

Other

Georgia

Deadline:

03/31/2027

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

by CTG

in Acute Myeloid Leukemia, Myelodysplastic Syndromes

Other

Illinois

Deadline:

04/01/2026

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

by CTG

in Acute Myeloid Leukemia, IDH1 Mutation

Other

Florida

Deadline:

02/01/2029

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

by CTG

in Acute Myeloid Leukemia, Myelodysplastic Syndromes

Other

Arizona

Deadline:

02/01/2029

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

by CTG

in Acute Myeloid Leukemia, Acute Monocytic Leukemia

Other

Oregon

Deadline:

05/01/2028

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

by CTG

in Acute Myeloid Leukemia, TP53

Other

Minnesota

Deadline:

01/27/2028

Two Step Haplo With Radiation Conditioning

by CTG

in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Aplastic Anemia, Adult T-Cell Leukemia/Lymphoma

Other

Pennsylvania

Deadline:

04/01/2032

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

by CTG

in Acute Myeloid Leukemia, Myelodysplastic Syndrome, Graft Versus Host Disease

Other

California

Deadline:

05/25/2027

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

by CTG

in Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Other

Texas

Deadline:

11/29/2027

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

by CTG

in Acute Myeloid Leukemia

Other

Arizona

Deadline:

12/01/2026

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

by CTG

in Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelofibrosis

Other

Pennsylvania

Deadline:

10/01/2026

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

by CTG

in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Chronic Myeloid Leukemia, BCR-ABL1 Positive

Other

California

Deadline:

01/01/2029

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

by CTG

in Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Anaplastic Large Cell Lymphoma, Adult Diffuse Large Cell Lymphoma

Other

Washington

Deadline:

01/10/2028

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

by CTG

in Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Biphenotypic Leukemia, T Acute Lymphoblastic Leukemia, Acute Bilineal Leukemia

Other

Texas

Deadline:

12/31/2026

Load more All clinical trials loaded.

Quality of Life Model for Older Patients With AML

Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

Two Step Haplo With Radiation Conditioning

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Acute Myeloid Leukemia

Filter Results:

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps